FRT vs RARE · rev $1.28B vs rev $350.0M
FRT (FRT) versus Ultragenyx (RARE) — a side-by-side from cached financials, not a winner call.
FRT (FRT) common stock.
Ultragenyx (RARE) is a biotechnology company listed on US.
Latest reported FRT revenue for 2025-12-31 was $1.28B. Net income was $411.1M. Revenue was up 6.4% from 2024-12-31 to 2025-12-31. FRT currently screens at market cap $0.
Latest reported RARE revenue for 2026-06-30 was $350.0M. Net income was -$277.0M. RARE currently screens at market cap $2.79B.
FRT currently screens at market cap $0. RARE currently screens at market cap $2.79B.
Not investment advice. Open the FRT and RARE stock pages for the full models.
Not investment advice.